HOME >> BIOLOGY >> NEWS
Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure

(Philadelphia, PA) The events that lead to cardiac hypertrophy, the enlargement of heart muscle cells, may be stopped by histone deacetylase (HDAC) inhibitors, a class of therapeutic agents currently under development as cancer drugs, according to researchers at the University of Pennsylvania School of Medicine. Cardiac hypertrophy is one of the leading causes of congestive heart failure, the most common diagnosis given for discharged hospital patients in the United States.

In the September issue of Journal of Clinical Investigation, the Penn researchers suggest novel genetic causes for and new therapeutic agents against cardiac hypertrophy and heart failure. Furthermore, the researchers demonstrate that anti-HDAC drugs can block the development of hypertrophy in animal models.

"In our studies, we determined that valproic acid, an HDAC inhibitor used to treat seizure disorders, is effective in preventing heart muscle cells from enlarging," said Jonathan A. Epstein, MD, Associate Professor in the division of Cardiovascular Medicine within Penn's Department of Medicine. "In recent years, drug companies have also begun developing more advanced HDAC inhibitors to treat cancer. These HDAC inhibitors may be among the first known medications to prevent cardiac hypertrophy."

Cardiac hypertrophy can be a healthy physiological response to events, such as aerobic exercise, where heart cells grow larger like any other well-conditioned muscle. Pathological hypertrophy, however, may result from genetic mutation or, most commonly, from the consequences of an unhealthy cardiovascular system.

"The exertion of pushing blood against high resistance in the setting of high blood pressure or overcompensation for heart muscle lost during a heart attack can cause heart muscle cells to enlarge," said Epstein. "While it might be helpful at first, hypertrophy can increase the stress placed on the heart and begin a downward spiral of events that ultimately leads
'"/>

Contact: Greg Lester
lesterg@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
15-Sep-2003


Page: 1 2

Related biology news :

1. Experimental drug shown to block mutant protein causing blood disease
2. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
3. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
4. Experimental Biology 2004 - Translating the Genome
5. Experimental Biology 2004 meets in Washington, D.C. April 17-21
6. Experimental hantavirus vaccine elicits strong antibody response in primates
7. Experimental Biology 2003 meets in San Diego April 11-15
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental gene switch increases lifespan with no ill effects
10. Experimental therapy stops allergic reactions in mice
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2018)... ... 25, 2018 , ... Maire Mayne, an evidence-based energy healer, ... to reduce inflammation and autoimmune disorders and improve overall immune response. , The ... The following data was reported:,     Over 180% increase in ...
(Date:8/23/2018)... ... August 21, 2018 , ... CRISPR-Cas9 gene editing strategies have ... for the robust functional interrogation of complex biological processes. Gene editing in primary ... the study of the autoimmunity, the understanding of host-pathogen dynamics that drive HIV ...
(Date:8/23/2018)... ... ... Lajollacooks4u is proud to have hosted a variety of groups this year – both new ... Qualcomm, Hewlett Packard, Sequenom and more, have all visited the La Jolla-based venue time and ... the reason clientele return is due to Lajollacooks4u’s signature team-building format, a way for teams ...
Breaking Biology News(10 mins):
(Date:8/31/2018)... ... 2018 , ... A recent expedition led by Dr. Blair ... of Industrial Science, the University of Tokyo, demonstrated how the use of autonomous ... of hard to reach deep sea ecosystems, like intermittently active methane seeps. Thanks ...
(Date:8/29/2018)... ... August 28, 2018 , ... ... announced today the successful completion of a $5.5 million funding round managed by ... Investment Fund, Commenda Capital, and Ellipsis Ventures. , “Our investment in Nanovis is ...
(Date:8/29/2018)... ... August 28, 2018 , ... Inc. Magazine has ... been ranked in 1138th place on the 27th annual Inc. 5000, the most ... represents the most successful companies within the American economy’s most dynamic segment – ...
(Date:8/29/2018)... YORBA LINDA, Calif. (PRWEB) , ... August 28, 2018 , ... ... engineers, and scientists from around the world, is proud to announce the launch of ... events LabRoots offers for a chance to win one of LabRoots most popular shirts. ...
Breaking Biology Technology:
Cached News: